DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) has proved to be an effective salvage therapy for refractory-relapsed MM patients. Little is known, however, about its potential as mobilizing therapy. The aim of this study was to evaluate the efficacy of DCEP in mobilizing PBSC and to define its toxicity. 
Peripheral blood stem cell (PBSC) transplantation following high-dose chemotherapy represents an integral part of front-line therapy in patients with multiple myeloma. 1, 2 Many studies have tried to define the optimal number of CD34 + stem cells for rapid hematopoietic reconstitution after PBSC transplantation. A number ranging between 2.0 and 5.0 ϫ 10 6 /kg has been reported to be sufficient for engraftment. [3] [4] [5] Unfortunately, not all patients mobilize an adequate number of PBSC to receive intensive conditioning regimens safely. The combination of high-dose cyclophosphamide (HDCTX) with hematopoietic growth factors is considered the standard mobilizing protocol to collect peripheral blood stem cells. [6] [7] [8] HDCTX, however, is associated with several side-effects such as nausea, emesis, neutropenic fever, sepsis, cardiac dysfunction, and hemorrhagic cystitis, with mortality rates of 1% to 2%. 7, 8 In addition, HDCTX has limited activity against the myeloma clone with little improvement of response after three or four cycles of VAD in newly diagnosed patients. 2 Tumor contamination of the graft is another crucial problem. As collection and reinfusion of monoclonal plasma cells might be associated with a shorter disease-free survival, a reduction of tumor contamination of the autograft through positive selection of CD34 + cells has been proposed. [9] [10] [11] [12] Whether the CD34 antigen is present on MM progenitor cells is still debated and, so far, there is no conclusive evidence that purging of graft reduces the risk of relapse or progression in multiple myeloma patients. On the other hand, it is known that in vitro purging techniques cause stem cell loss and depletion of T and B lymphocytes from the graft, with consequent delayed immune recovery and increased infectious complications in transplanted patients. 9, 13, 14 To reduce tumor contamination of the graft, an alternative is to improve in vivo debulking using more intensive chemotherapy programs during the mobilizing phase. 15 We used a combination of dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) with the aim of treating myeloma and at the same time mobilizing PBSC. The rationale was: (1) DCEP has proved to be an effective and well tolerated regimen for refractory MM patients; (2) the side-effects of this combination are acceptable even in the fragile setting of refractory patients; (3) schemes including cisplatin, in association with G-CSF, have been reported as good mobilizing protocols in cancer patients. To our knowledge, this is the first study on DCEP as a mobilizing regimen in multiple myeloma patients. The aim of this study was to evaluate its efficacy in mobilizing stem cells and to define its toxicity.
Materials and methods

Patients
Between January 2000 and February 2001, 55 patients (30 males and 25 females) with myeloma received DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) in 4-day infusions followed by G-CSF as part of high-dose programs including autologous transplantation. The median age was 54 years (range 30-68). Of 55 patients, 40 had previously received VAD only, and 15 alkylating agents. Patients were restaged at the start of DCEP. The stages by Durie and Salmon criteria were as follows: 36 patients stage I; six stage II; 13 stage III. With the aim of identifying factors correlated with the number of CD34 + cells mobilized, the therapeutic history of the patients and the following clinical and laboratory parameters at the start of DCEP were evaluated: stage, interval from first treatment to DCEP, previous exposure to alkylating agents, type of M component, Bence-Jones proteinuria, skeletal involvement, age, WBC and platelet counts, hemoglobin level, bone marrow plasmacytosis, creatinine, urea. WBC and platelet counts, hemoglobin level, creatinine, and urea were evaluated as categorical variables with respect to the normal ranges. We used a cut-off of 50% for bone marrow plasmacytosis, and of 6 months as interval from first treatment to DCEP.
Patients received DCEP (dexamethasone 40 mg for 4 days, and 4-day continuous infusion of daily doses of cyclophosphamide 400 mg/m 2 , etoposide 40 mg/m 2 , cisplatin 10 mg/m 2 ) as mobilizing therapy, followed by hemopoietic growth factor (G-CSF 5 g/kg/day) starting 48 h after the end of chemotherapy. PBSC were collected with a continuous-flow blood cell separator (Spectra, COBE BCT, Lakewood, CO, USA), processing a total volume per leukapheresis of two to three blood mass volumes.
Flow cytometry
Aliquots of the leukapheresis products were incubated with phycoerythrin-conjugated monoclonal anti-CD34 (HPCA2, Becton Dickinson, San Jose, CA, USA) for 15 min at 20°C, then lysed with a lyse-no-wash standard assay and finally incubated for 10 min at 4°C. Cells were processed with FACSort analyzer (Becton Dickinson). Data acquisition was performed with Cellquest software (Becton Dickinson).
Cryopreservation
Cells, diluted in dimethylsulfoxide (DMSO) solution at a final DMSO concentration of 10%, were frozen to −160°C by means of a KRYO II Series freezer (Planer R203) at a controlled rate and then stored in the liquid phase of nitrogen.
Statistical analysis
Continuous variables are reported as median and range, and categorical variables as count and relative frequency. For each dichotomized clinical parameter, analysis of variance (ANOVA) techniques were used to test for a difference in the mean numbers of collected CD34
+ cells between the two groups of patients defined according to the clinical parameter. Because of the small sample size, no multivariate analysis was carried out. Fisher's exact test was used to assess the association between dichotomous clinical parameters and a yield of CD34 + cells below the threshold of 4 ϫ 10 6 /kg. The dichotomous parameters significantly associated with a yield of CD34 + cells below the threshold were then considered as risk factors for a low CD34
+ collection. Finally, the number of risk factors present in each patient was used to build a scoring system to predict an inadequate yield of CD34 + cells. All tests were two-tailed, with a significance level P р 0.05.
Results
The clinical and laboratory characteristics of patients and prior chemotherapy history are reported in Table 1 . Of the 55 patients, 15 (27%) had been previously exposed to Table 1 Characteristics of patients at the start of DCEP alkylating agents. The median interval from the start of first treatment to DCEP was 4 months (range 2-54). Peripheral blood counts are reported as means Ϯ standard deviation. 
Progenitor cell collections
Toxicity of DCEP
Toxicities following DCEP were always mild and tolerable. Granulocyte counts and Hb levels never dropped below 1.0 ϫ 10 9 /l and 10 g/dl, respectively, as a consequence of treatment. The only two patients who needed packed red cells transfusion had low hemoglobin levels before starting DCEP. No patient had thrombocytopenia Ͻ50 000 ϫ 10 9 /l. No patient needed hospitalization for septic complications. The most frequent extra-hematologic toxicity was nausea related to the administration of cisplatin, which was mild or moderate and always easily controlled with antiemetic therapy.
Factors affecting the yield of peripheral stem cells
A statistical analysis was performed of pre-DCEP parameters to evaluate their influence on stem cell collections. In univariate analysis, a WBC count Ͻ4.0 ϫ 10 9 /l (P = 0.038), platelet count Ͻ150 ϫ 10 9 /l (P = 0.012), Hb Ͻ10 g/dl (P = 0.029), marrow plasmacytosis Ͼ50% (P = 0.036), previous exposure to alkylating agents (P = 0.011), and an 
CD34
+ cells/kg, we also analyzed these variables with respect to CD34 + cells harvested considered in a dichotomous fashion. So, platelets Ͻ150 ϫ 10 9 /l (P = 0.004), Hb Ͻ10 g/dl (P = 0.033), prior exposure to alkylating agents (P = 0.011), and a pre-DCEP interval Ͼ6 months (P = 0.018) were confirmed risk factors for collections below the cut-off of 4 ϫ 10 6 CD34 + cells/kg. On the basis of the four factors negatively associated with CD34
+ cell collection, patients were scored as having from 0 to 4 factors. The analysis was performed considering the number of CD34 + cells as a continuous, as well as a dichotomous variable. Patients presenting with more than one risk factor showed a high probability of collecting lower numbers of stem cells (P = 0.002), in particular, less than 4 ϫ 10 6 /kg (P = 0.003). Figure 1 shows the likelihood of mobilizing Ͼ4 × 10 6 /kg CD34 + cells according to the number (0, 1, 2, 3) of adverse factors. Only one patient presented all four risk factors and then it was not possible to apply the logistic regression.
Discussion
This is the first report investigating the efficacy of a DCEP protocol in combination with G-CSF as mobilizing therapy in multiple myeloma patients. High-dose therapy followed by autologous stem cell transplantation is the therapy of choice for patients with multiple myeloma. Most high-dose protocols include an induction phase with VAD-based regimens, because this combination has no negative effects on PBSC collection. The most commonly used mobilizing regimen is HDCTX which has proved to be effective in harvesting adequate numbers of stem cells. However, because of its limited anti-myeloma activity, HDCTX has little capacity to reduce the tumor burden further.
More intensive chemotherapy regimens have been reported to have a better capacity of purging in vivo in MM patients. In particular, Cook et al 16 ide 4 g/m 2 alone, finding the triple combination superior in mobilizing stem cells. Stewart and colleagues 15 reported the superiority of a similar scheme in mobilizing blood stem cells when compared with less intensive chemotherapy regimens. All these intensive protocols, however, created significant hematologic and extrahematologic problems such as transfusion requirement, septic complications, and need for hospitalization.
The antitumor efficacy of DCEP has been proved in the difficult setting of refractory patients. 19 This combination is also included in ongoing trials as front line, 20 or consolidation therapy after double transplant in MM patients. 21 In our hands, preliminary analysis confirmed the efficacy of DCEP in reducing tumor burden (data not shown). This study, focused on the mobilization activity of the combination, clearly demonstrates that DCEP is an effective mobilizing regimen for transplant-eligible patients with MM. In fact, in the entire population of MM patients studied, 87% of cases could yield Ͼ2 ϫ 10 6 CD34 + cells/kg, and 75% yielded more than 4 ϫ 10 6 CD34 + cells/kg. Notably, 10 out of 15 patients (67%) previously exposed to alkylating agents mobilized enough CD34
+ cells to support high-dose melphalan-based autologous transplantation. These results compare favorably with those reported with CTX at 4 or 7 g/m 2 , 6, 16, 18, 22 and are similar to those obtained with more intensive combination protocols. 15, 16 These latter studies, however, showed considerable toxicity with prolonged neutropenia which entailed in the majority of patients septic complications, marked anemia, and thrombocytopenia with need for transfusions and hospitalization. By contrast, DCEP was always well tolerated with very mild sideeffects. Actually, no patient needed to be hospitalized for septic complications, and only two patients, who were anemic at the start of DCEP, received packed red cell transfusions. No instances of neutropenia Ͻ1.0 ϫ 10 9 /l or thrombocytopenia Ͻ50 ϫ 10 9 /l were observed. All patients were managed in an outpatient setting apart from the 4 days of DCEP infusion.
The evaluation of the factors affecting the yield of CD34 + cells showed in univariate analysis that WBC count, platelet count, Hb level, plasmacytosis, previous exposure to alkylating agents, and an interval from the first treatment to DCEP Ͼ6 months, were statistically correlated with the collection of low numbers of CD34 + cells. Dichotomizing the number of CD34 + cells collected as more or less than 4 ϫ 10 6 , only platelets Ͻ150 ϫ 10 9 /l, Hb Ͻ10 g/dl, prior exposure to alkylating agents, and a Ͼ6 months interval maintained their negative influence on stem cell yield. We have previously demonstrated the utility of a scoring system to identify patients at a high risk of yielding insufficient numbers of CD34 + cells. 22 In this report, we also show that the presence of more than one of the above-identified risk factors implies a high probability of collecting lower numbers of stem cells, in particular less than 4 ϫ 10 6 /kg, which is considered the standard target for a rapid recovery after PBSC-supported high-dose therapy in MM.
In conclusion, DCEP is an effective regimen for mobilizing peripheral blood progenitor cells in transplant-eligible patients with multiple myeloma. This combination is always well tolerated with very mild side-effects, allowing easy management of the mobilization phase.
